JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

IgG Depleted Baby Rabbit Complement

IgG Depleted Baby Rabbit Complement

Complement is produced under controlled conditions from large pools of New Zealand White rabbits that are 21-28 days old then depleted of IgG antibodies further reducing heterophile antibody activity. Useful in serum bactericidal and opsonophagocytic assays.

Skip to the end of the images gallery

Bottle of baby rabbit complement

Skip to the beginning of the images gallery

Product Datasheet

Product Datasheet

Specifications

Physical State: Frozen Liquid

Storage: -70°C or below

Applications: Assay Development & Validation, Vaccine Development, Non-Clinical & Preclinical Studies

Learn more

Size:

Product Code: Select size

Quantity:

Custom/Bulk request

Bulk Requirements for Human Serum

More 1 L

From
$36.00

Lead time on this item is currently: 2-4 Weeks

Need help? Ask a Specialist Contact Us OR +1 (800) 643-3426

Product Overview

Product Overview
Application:	Assay Development & Validation, Vaccine Development, Non-Clinical & Preclinical Studies
Storage Conditions:	-70°C or below
Shipping Conditions:	Dry ice
Species:	Rabbit
Application Notes:	Suitable for functional antibody assays (SBA-Serum Bactericidal Assay, MOPA/OPA- Multiplexed /Opsonophagocytic Killing Assay) for vaccine evaluation. Complement components are extremely heat-sensitive; for best results, thaw complement on ice or in a cold water bath. Aliquots may be made and frozen at -70°C or below. Avoid multiple freeze-thaw cycles. When a working aliquot is thawed, do not re-freeze remaining complement, but discard it.
Guarantee:	Product quality is guaranteed to meet Pel-Freez Biologicals’ specifications for 1 year from the date of receipt by the customer as long as the product is stored in accordance with the indicated storage conditions.
Testing:	Hemolytic Titer: ≥1:16 \| Endotoxin: ≤ .0 EU/mL \| Residual IgG: <3.5% \| Sterility: Passed, 14 day sterility testing \| Mycoplasma: Negative \| Viral: Negative
Packaging:	Poly bottle
Product Attributes:	Sterile, Off-the-Clot (OTC)
Product Types:	Complement
Physical State:	Frozen Liquid
Depletion Process:	IgG Depleted
Absorption:	Unabsorbed

Product Applications

Assay development & validation
Immunoassays
Vaccine development
Serum bactericidal assay
Opsonophagocytic assay

Documents & Datasheets

Product Datasheet

BRC Product Information Sheet

Datasheet for 31061 Rabbit 3-4 Week Complement Rev 02

Safety Datasheet

SDS for 31061 Rabbit Complement 3-4 Week

COA

Certificate of Analysis for 31061 Lot 02243

Certificate of Analysis for 31061 Lot 00843

Certificate of Analysis for 31061 Lot 01543

Certificate of Analysis for 31061 Lot 02943-A

Certificate of Analysis for 31061 Lot 02943-B

Certificate of Analysis for 31061 Lot 03643

Certificate of Analysis for 31061 Lot 07143

Certificate of Analysis for 31061 Lot 08543-A

Certificate of Analysis for 31061 Lot 08543-B

Certificate of Analysis for 31061 Lot 05043

Certificate of Analysis for 31061 Lot 04343

Certificate of Analysis for 31061 Lot 05743-B

Certificate of Analysis for 31061 Lot 05743-A

Certificate of Analysis for 31061 Lot 09243

Certificate of Analysis for 31061 Lot 06443

Certificate of Analysis for 31061 Lot 09943

Certificate of Analysis for 31061 Lot 12942-B

Certificate of Analysis for 31061 Lot 14342

Certificate of Analysis for 31061 Lot 13642

Certificate of Analysis for 31061 Lot 11343

Certificate of Analysis for 31061 Lot 10643

Certificate of Analysis for 31061 Lot 15742

Certificate of Analysis for 31061 Lot 16442

Certificate of Analysis for 31061 Lot 17142

Certificate of Analysis for 31061 Lot 17842-B

Certificate of Analysis for 31061 Lot 17842-A

Certificate of Analysis for 31061 Lot 21342-B

Certificate of Analysis for 31061 Lot 23442

Certificate of Analysis for 31061 Lot 22742

Certificate of Analysis for 31061 Lot 21342-A

Certificate of Analysis for 31061 Lot 19942

Certificate of Analysis for 31061 Lot 20642

Certificate of Analysis for 31061 Lot 24142-A

Certificate of Analysis for 31061 Lot 24142-B

Certificate of Analysis for 31061 Lot 25542

Certificate of Analysis for 31061 Lot 26242

Certificate of Analysis for 31061 Lot 26942-B

Certificate of Analysis for 31061 Lot 26942-A

Certificate of Analysis for 31061 Lot 28342

Certificate of Analysis for 31061 Lot 29742-A

Certificate of Analysis for 31061 Lot 29742-B

Certificate of Analysis for 31061 Lot 29042

Certificate of Analysis for 31061 Lot 31142

Certificate of Analysis for 31061 Lot 33942

Certificate of Analysis for 31061 Lot 34642

Certificate of Analysis for 31061 Lot 01841

Certificate of Analysis for 31061 Lot 02541

Certificate of Analysis for 31061 Lot 04241

Certificate of Analysis for 31061 Lot 03941

Certificate of Analysis for 31061 Lot 05341-A

Certificate of Analysis for 31061 Lot 05341-B

Certificate of Analysis for 31061 Lot 11641

Certificate of Analysis for 31061 Lot 10241-B

Certificate of Analysis for 31061 Lot 08141

Certificate of Analysis for 31061 Lot 06741

Certificate of Analysis for 31061 Lot 10241-A

Certificate of Analysis for 31061 Lot 13041

Certificate of Analysis for 31061 Lot 14441

Certificate of Analysis for 31061 Lot 15841-A

Certificate of Analysis for 31061 Lot 15841-B

Certificate of Analysis for 31061 Lot 15841-C

Certificate of Analysis for 31061 Lot 20041

Certificate of Analysis for 31061 Lot 22841-B

Certificate of Analysis for 31061 Lot 22841-A

Certificate of Analysis for 31061 Lot 20741

Certificate of Analysis for 31061 Lot 18341

Certificate of Analysis for 31061 Lot 24241

Certificate of Analysis for 31061 Lot 25641

Certificate of Analysis for 31061 Lot 27041

Certificate of Analysis for 31061 Lot 28441

Certificate of Analysis for 31061 Lot 29841

Certificate of Analysis for 31061 Lot 35441

Certificate of Analysis for 31061 Lot 31241

Certificate of Analysis for 31061 Lot 34041-A

Certificate of Analysis for 31061 Lot 34041-B

See more...

See less...

Product References

Human IgM inhibits the formation of titan-like cells in Cryptococcus neoformans
Nuria Trevijano-Contador et al. Human IgM inhibits the formation of titan-like cells in cryptococcus neoformans. Infect. Immun. 88, (2020).

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
Kwon, J.-C. et al. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). Animal Cells Syst. (Seoul). 1–13 (2021).

Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes
Salehi, S., Hohn, C. M., Penfound, T. A. & Dale, J. B. Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Streptococcus pyogenes . mSphere 3, (2018).

Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella
Ramachandran, G. et al. Functional activity of antibodies directed towards Flagellin proteins of non-typhoidal Salmonella. PLoS One 11, 151875 (2016).

Cryptococcus neoformans Coinfection Dampens the TNF-α Response in HIV-1-Infected Human THP-1 Macrophages
Kalem, M. C., Humby, M. S., Wohlfert, E. A., Jacobs, A. & Panepinto, J. C. Cryptococcus neoformans Coinfection Dampens the TNF-α Response in HIV-1-Infected Human THP-1 Macrophages. mSphere 6, (2021).

Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus …
St. Michael, F. et al. Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus mutans. Glycoconj. J. 35, 53–64 (2018).

Rational design and evaluation of an artificial Escherichia coli K1 protein vaccine candidate based on the structure of OmpA
Gu, H. et al. Rational design and evaluation of an artificial Escherichia coli K1 protein vaccine candidate based on the structure of OmpA. Front. Cell. Infect. Microbiol. 8, 172 (2018).

Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice
Zhang, X. et al. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice. Vaccine 36, 1047–1054 (2018).

Quality improvement of capsular polysaccharide in streptococcus pneumoniae by purification process optimization
Lee, C. et al. Quality Improvement of Capsular Polysaccharide in Streptococcus pneumoniae by Purification Process Optimization. Front. Bioeng. Biotechnol. 8, (2020).

Validity of Enzyme-Linked Immunosorbent Assay (ELISA) as a correlate of protection of meningococcal C conjugated vaccine in adolescents with HIV infection
Daniela Vinhas, B. et al. Validity of Enzyme-Linked Immunosorbent Assay (ELISA) as a correlate of protection of meningococcal C conjugated vaccine in adolescents with HIV infection. J. Vaccines Immunol. 6, 001–007 (2020).

Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus
Choi, M. J. et al. Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus. Hum. Vaccines Immunother. 16, 1338–1344 (2020).

Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease
Scully, I. L. et al. Performance of a four-antigen staphylococcus aureus vaccine in preclinical models of invasive S. aureus disease. Microorganisms 9, 1–13 (2021).

A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.
Ozdilek, A. et al. A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies. MBio (2021).

Opsonophagocytic Antibodies of Intravenous Immunoglobulin Preparations against Seven Streptococcus agalactiae Serotypes
Lee, J. H., Kim, H. W., Cha, J. & Kim, K. H. Opsonophagocytic antibodies of intravenous immunoglobulin preparations against seven streptococcus agalactiae serotypes. Pediatr. Infect. Vaccine 28, 21–30 (2021).

An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera
McGregor, R., Jones, S., Jeremy, R. M., Goldblatt, D. & Moreland, N. J. An Opsonophagocytic Killing Assay for the Evaluation of Group A Streptococcus Vaccine Antisera. in Methods in Molecular Biology vol. 2136 323–335 (Humana Press Inc., 2020).

Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines
Xu, H. et al. Expression of bordetella pertussis antigens fused to different vectors and their effectiveness as vaccines. Vaccines 9, (2021).

Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice.
McGuinness, D. et al. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine (2021).